Early and Long Term Results of Our Open Heart Surgical Operations in the Presence of Active Oncological Diseases
Mehmet Erdem Toker1
, Cüneyt Arkan1, Ahmet Erdal Taşçı2, Erdal Polat3, Üzeyir Yılmaz1, Tunahan Sarı1, Ömer Faruk Akardere1
1Clinic of Cardiovascular Surgery, Koşuyolu High Specialization Training and Research Hospital, İstanbul, Turkey
2Clinic of Chest Surgery, Koşuyolu High Specialization Training and Research Hospital, İstanbul, Turkey,
3Clinic of Gastroenterology Surgery, Koşuyolu High Specialization Training and Research Hospital, İstanbul, Turkey
Keywords: Coronary artery bypass grafting; cardiopulmonary bypass; lung cancer; breast cancer
Abstract
Introduction: Active cancer and heart disease, which share similar environmental and biological characteristics, can occur concomitantly. Open heart surgery may be required for these patients when indicated. This study aims to demonstrate the early and long-term results and discuss the intervention strategy in patients with different types of active malignancies, who underwent open-heart surgery.
Patients and Methods: Between January 2012 and May 2020, open-heart surgery was performed on 10 patients with active malignancies. The mean age was 65.5 (52-77), and four of the patients were female. Two patients were operated on urgently due to advanced pleural effusion. AVR+CABG, CABG, CABG+left upper lobectomy, and AVR+MVR were performed in four patients with lung cancer; AVR+CABG were performed in one patient with colon cancer; CABG was performed in four patients each with one of the following conditions: lymphoma, breast cancer, essential thrombocytosis, meningioma); and mass resection operation from the left atrium and left ventricle was performed in one patient with osteosarcoma.
Results: Eight patients were discharged and two patients died in the early postoperative period. Postoperative left hemiparesis developed in one patient. Six-month, one-year and five-year survival rates were 79%, 37.5% and 25%, respectively.
Conclusion: Open-heart surgery can be successfully performed with acceptable mortality and morbidity rates on the high-risk patient group with active cancer.
The approval for this study was obtained from Kartal Koşuyolu High Training and Research Hospital Clinical Research Ethics Committee (Decision no: 2020/13/395, Date: 18.12.2020).
This is retrospective study, we could not obtain written informed consent from the participants.
Externally peer-reviewed.
Externally peer-reviewed.
The authors declared that there was no conflict of interest during the preparation and publication of this article.
The authors declared that this study has received no financial support.